January 2013 in “Medical & Pharmaceutical Journal of Chinese People's Liberation Army” In this study, catgut embedding combined with moxibustion and bloodletting was reported to be more effective than finasteride for androgenetic alopecia, reducing hormonal imbalances and improving patient quality of life.
November 2024 in “Pharmaceutics” This study found that dutasteride-loaded transfersomes, compared to traditional liposomes, better target hair follicles by releasing the drug in a more controlled manner, as shown in vitro with enhanced follicular targeting (Tf = 0.32 versus 0.15, p < 0.005) using porcine ear skin.
November 2022 in “Molecular Pharmaceutics” This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.
7 citations
,
April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences” This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.
1 citations
,
December 2013 in “Journal of pharmacy and pharmaceutical sciences” This study concluded that vitamins and protein tablets were more effective for reducing hair fall than shampoos and other medications, while herbal oils were preferable to chemical-based hair fall solutions.
January 2026 in “Journal of Applied Pharmaceutical Science” This study identified that the ethanol extract of Selaginella doederleinii may enhance the effectiveness of doxorubicin in treating cervical cancer cells while also providing chemopreventive benefits.
December 2025 in “VNU Journal of Science Medical and Pharmaceutical Sciences” This review synthesizes evidence supporting the efficacy of PRP in dermatological conditions like wound healing and alopecia, but emphasizes the need for standardized protocols and larger randomized controlled trials.
August 2025 in “International Journal of Pharmaceutics” In AGA animal models, this study found that finasteride-loaded microspheres provided rapid and sustained dihydrotestosterone suppression, promoting hair regrowth through dual-phase drug release.
July 2025 in “International Journal of Pharmaceutical Sciences Review and Research” This case report documented a 20-year-old male with alopecia areata who experienced slight hair regrowth following treatment with cyclosporine and methylprednisolone, highlighting the importance of individualized treatment plans and consideration of medication side effects.
July 2025 in “International Journal of Pharmacy and Pharmaceutical Science” This review highlights the potential of herbal remedies as complementary options for breast cancer care, noting benefits like immune modulation and reduced chemotherapy side effects, in contrast to conventional treatments that often cause significant side effects and long-term health issues.
April 2025 in “International Journal of Pharmaceutics” Liposomes improve minoxidil delivery to hair follicles, enhancing treatment for hair loss.
December 2024 in “Asian Journal of Pharmaceutical and Clinical Research” This study reviews the performance and safety of synthetic medications like minoxidil and finasteride compared to herbal remedies such as saw palmetto for treating alopecia, highlighting the need for more research to better understand their therapeutic roles and optimize patient care.
October 2024 in “International Journal of Pharmaceutics” This study found that a topical formulation with nanostructured lipid carriers containing finasteride significantly restored hair follicles in androgenetic alopecia-induced rats without systemic absorption, suggesting its potential for safer and effective AGA treatment.
September 2023 in “Pharmaceuticals” This study found that nanoparticles containing minoxidil and betamethasone improved drug delivery to hair follicles, with lipidic nanoparticles significantly enhancing minoxidil and betamethasone penetration compared to control, making them a promising option for alopecia areata treatment with reduced side effects.
4 citations
,
May 2022 in “Future Journal of Pharmaceutical Sciences” This study found that a melatonin-loaded microemulsion exhibited controlled release and significant stratum corneum deposition in ex vivo permeation tests, suggesting its potential for further evaluation in treating androgenic alopecia.
1 citations
,
April 2018 in “Asian Journal of Pharmaceutical Research and Development” This study found that a formulated herbal hair oil using ingredients like Amla, Almond, and Neem showed promising results in promoting hair growth, protecting against dandruff, and providing shine, outperforming a marketed hair oil in evaluations.
159 citations
,
July 2014 in “Molecular pharmaceutics” This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.
February 2026 in “International Journal of Pharmaceutics”
52 citations
,
February 2006 in “Current pharmaceutical design” This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.
December 2019 in “Global pharmaceutical sciences review” This review covers the epidemiology, risk factors, and diagnosis of alopecia, highlighting existing treatments like finasteride and minoxidil but focusing on new strategies without providing clinical results.
32 citations
,
March 2013 in “Journal of Pharmaceutical Sciences” This study observed that iontophoresis significantly improved the delivery of minoxidil sulfate to hair follicles compared to passive methods, suggesting potential benefits for alopecia treatment.
19 citations
,
November 2017 in “Journal of Pharmaceutical Sciences” This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.
January 2025 in “International Journal of Pharmaceutics” In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.
June 2022 in “Journal of pharmaceutical research international” This article discusses scalp dermatoscopy and home CI therapy as promising diagnostic and treatment options for alopecia areata but reports no new clinical results.
March 2024 in “International journal of pharmaceutical sciences and drug research” In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.
January 2024 in “Journal of Applied Pharmaceutical Science” This study identified procyanidin B2 and leucopelargonidin from Saraca asoca as potential inhibitors in PCOS by showing high binding energy scores against key enzymes involved in estrogen and testosterone biosynthesis.
9 citations
,
January 2014 in “DARU Journal of Pharmaceutical Sciences” This study found that Cuscuta reflexa extracts promoted hair regrowth and follicular proliferation in cyclophosphamide-induced hair loss in male rats.
January 2018 in “journal of applied pharmaceutical science” This study found that biomimetic peptides may enhance the expression of growth factors in the hair follicles of patients experiencing telogen effluvium.
March 2023 in “International Journal of Applied Pharmaceutics” In this study, researchers formulated a topical gel containing β-sitosterol for alopecia treatment and found it demonstrated good 5 alpha reductase inhibitory activity in vitro, comparable to a commercial product, indicating its potential for further antiandrogenic activity investigation.
August 2024 in “Saudi Journal of Medical and Pharmaceutical Sciences” In this study, PRP combined with minoxidil was found to be more effective in improving hair counts in androgenetic alopecia patients compared to minoxidil alone or with dermaroller, showing significant improvements at both 3 and 5 months.